These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 10210604)
1. Factors involved in the success of antimuscarinic treatment. Abrams P; Larsson G; Chapple C; Wein AJ BJU Int; 1999 Mar; 83 Suppl 2():42-7. PubMed ID: 10210604 [No Abstract] [Full Text] [Related]
2. Darifenacin in the treatment of overactive bladder. Parsons M; Robinson D; Cardozo L Int J Clin Pract; 2005 Jul; 59(7):831-8. PubMed ID: 15963212 [TBL] [Abstract][Full Text] [Related]
3. [Treatment of the overactive bladder with detrusitol]. Golomb J Harefuah; 2000 Dec; 139(11-12):467-70. PubMed ID: 11341197 [No Abstract] [Full Text] [Related]
4. Tolterodine for overactive bladder. Med Lett Drugs Ther; 1998 Oct; 40(1038):101-2. PubMed ID: 9813595 [No Abstract] [Full Text] [Related]
5. Tolterodine once-daily in treatment of the overactive bladder. Peters KM; Huang RR Urology; 2001 Nov; 58(5):829-32. PubMed ID: 11711378 [No Abstract] [Full Text] [Related]
6. Treatment of the overactive bladder with tolterodine, a new muscarinic receptor antagonist. Messelink EJ BJU Int; 1999 Mar; 83 Suppl 2():48-52. PubMed ID: 10210605 [No Abstract] [Full Text] [Related]
7. Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations. Hashim H; Abrams P Drugs; 2004; 64(15):1643-56. PubMed ID: 15257626 [TBL] [Abstract][Full Text] [Related]
8. The pharmacotherapy of overactive bladder. Athanasopoulos A Expert Opin Pharmacother; 2011 May; 12(7):1003-5. PubMed ID: 21291348 [TBL] [Abstract][Full Text] [Related]
9. Antimuscarinics for the treatment of overactive bladder: current options and emerging therapies. Hegde SS; Mammen M; Jasper JR Curr Opin Investig Drugs; 2004 Jan; 5(1):40-9. PubMed ID: 14983972 [TBL] [Abstract][Full Text] [Related]
10. [Bladder storage and voiding dysfunctions : Side effects of drug therapy]. Wolfesberger J; Falkensammer CE; Madersbacher S Urologe A; 2017 Apr; 56(4):456-464. PubMed ID: 28233038 [TBL] [Abstract][Full Text] [Related]
11. [Medical treatment of voiding problems in men]. Andersen JT; Nordling J; Walter S Ugeskr Laeger; 2007 May; 169(20):1892-4. PubMed ID: 17553364 [TBL] [Abstract][Full Text] [Related]
12. [Changes in muscarinic receptors of the aging bladder]. Andersson KE; Schröder A Urologe A; 2004 May; 43(5):552-6. PubMed ID: 15098089 [TBL] [Abstract][Full Text] [Related]
14. Detrol LA and Diropan XL for overactive bladder. Med Lett Drugs Ther; 2001 Apr; 43(1101):28. PubMed ID: 11283473 [No Abstract] [Full Text] [Related]
16. Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Kelleher CJ; Reese PR; Pleil AM; Okano GJ Am J Manag Care; 2002 Dec; 8(19 Suppl):S608-15. PubMed ID: 12516955 [TBL] [Abstract][Full Text] [Related]
17. Improvement of urinary dysfunction after kidney transplantation by administration of the antimuscarinic agent--prospective randomized controlled study. Tsunoyama K; Ishida H; Shimizu T; Omoto K; Tanabe K Transplantation; 2012 Mar; 93(6):597-602. PubMed ID: 22245877 [TBL] [Abstract][Full Text] [Related]
18. Solifenacin in the management of the overactive bladder syndrome. Robinson D; Cardozo L Int J Clin Pract; 2005 Oct; 59(10):1229-36. PubMed ID: 16178992 [TBL] [Abstract][Full Text] [Related]
19. [Treatment of overactive bladder]. Hunskår S Tidsskr Nor Laegeforen; 2005 Aug; 125(15):2029-30. PubMed ID: 16100546 [No Abstract] [Full Text] [Related]
20. Lower urinary tract symptoms (LUTS) in men: thinking beyond the prostate. Elsamra S; Ellsworth PS Med Health R I; 2010 Feb; 93(2):53-6. PubMed ID: 20329627 [No Abstract] [Full Text] [Related] [Next] [New Search]